News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GBI Research Release: Cold-Chain Storage Critical to Pharma's Future



6/25/2012 11:34:20 AM

NEW YORK (GBI Research), 21 June 2012 - As temperature sensitive drugs become more prevalent, pharmaceutical companies are increasing reliance, and spending, on cold-chain storage, according to a report by business intelligence experts GBI Research.

The new report* states that pharmaceutical firms around the world are investing more and more in this storage solution in response to the increase in treatments such as vaccines, biologics, specialty pharmaceuticals and personalized medicines that must be maintained at low temperatures.

Blockbuster vaccines such as Prevnar 13 and Gardasil (with 2011 sales of $3.6 billion and $1.2 billion respectively) require storage in cold temperatures, as do top selling monoclonal antibodies Avastin, Enbrel, Rituxan, Herceptin and Remicade.

But this trend is not limited to branded drugs; GBI Research also expects generic products to drive cold-chain storage implementation, as prescriptions have more than doubled since 2000. The demand for generic medications in emerging markets such as India, China and Brazil will correspondingly increase the need for low temperature handling and transportation facilities. As a result, it is estimated that the value of generic drug sales that require cold-chain storage will exceed $120 billion by 2018.

With lower production costs, skilled workforces and favorable regulatory environments, pharmaceutical companies are outsourcing manufacturing operations to developing Asian countries. GBI Research predicts a sizeable boost in spending on cold-chain storage resources for this region, from $1.1 billion in 2011, to $2.5 billion in 2018 – the greatest percentage increase of any region.

In comparison, the US is predicted to escalate investment in this area from $2.6 billion to $3.5 billion, whereas Europe will increase expenditure more modestly from $2 billion to $2.2 billion.

* Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits This report analyzes the overall Supply Chain Management (SCM) scenario and provides profiles of the leading participants in the pharmaceutical supply chain in the US.

This report is built using data and information sourced from proprietary databases, as well as primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

-ABOUT GBI RESEARCH-

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

For more information, please contact our Press Office on +44 (0)1204 543 528 or at pr@gbiresearch.com


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES